Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with AML (a type of blood cancer), ALL (another type of blood cancer), or MDS (a bone marrow disorder), and your doctors have decided you need a stem cell transplant from a partially matched donor.
- You are 18 years of age or older at the time of signing the consent form.
- You are generally able to carry out normal daily activities, as measured by a standard health scoring system (confirm with trial site).
- Your heart is pumping blood effectively enough to meet a minimum level set by the trial.
- Your lungs are working well enough, either fully or at least at a minimum level measured by a breathing test.
- Your liver and kidneys are functioning adequately, as shown by standard blood tests.
Who may not be able to join:
- You have previously had a stem cell transplant from another person's cells.
- You have received another type of cell-based treatment within 4 weeks before the planned date of receiving the trial treatment.
- You are currently taking part in another clinical trial, or have received an experimental treatment within 4 weeks before the planned date of receiving the trial treatment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Fabio CICERI, MD, Pr., I.R.C.C.S. Ospedale San Raffaele
Phone: +32 (0) 492 46 23 55
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Occurrence of Unexpected Unacceptable Toxicities (UUT) following the administration of SMART101.; CD4+ T cell count.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.